XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Sales revenues:    
Total sales revenues $ 86,233 $ 77,871
Costs of sales:    
Total costs of sales 44,177 36,681
Gross profit 42,056 41,190
Operating expenses:    
Product development 9,836 8,064
Sales and marketing 6,959 7,042
General and administrative 14,952 13,426
Amortization of acquisition-related intangibles 4,014 3,672
Total operating expenses 35,761 32,204
Operating income 6,295 8,986
Other income (expense):    
Other income 267 157
Gain on contingent consideration 0 1,250
Interest expense (2,669) (917)
Total other (expense) income (2,402) 490
Income before taxes 3,893 9,476
Provision for income taxes 809 1,363
Net income $ 3,084 $ 8,113
Net income per common share-basic (in dollars per share) $ 0.21 $ 0.55
Net income per common share-diluted (in dollars per share) $ 0.21 $ 0.55
Weighted average shares outstanding used in per common share computations:    
Basic (in shares) 14,136 14,381
Diluted (in shares) 14,136 14,381
RCM    
Sales revenues:    
Total sales revenues $ 48,631 $ 40,511
Costs of sales:    
Total costs of sales 27,183 20,398
EHR    
Sales revenues:    
Total sales revenues 35,191 34,763
Costs of sales:    
Total costs of sales 16,348 15,339
Patient Engagement    
Sales revenues:    
Total sales revenues 2,411 2,597
Costs of sales:    
Total costs of sales $ 646 $ 944